MT1G and cancer: Furthermore, Nrf2 can promote the expression of metallothionein 1G (MT1G), an important negative regulator of ferroptosis, through the cystathionase pathway, leading to the resistance of cancer cells to sorafenib (Sun et al., 2016a).